Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.
Biontech, a Germany-based immuno-oncology therapy developer spun out of Johannes Gutenberg University Mainz, closed a $325m series B round yesterday led by financial services group Fidelity Management & Research.
Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office as well as unnamed new and existing investors took part in the round.
Biontech previously obtained $91.5m in equity funding from pharmaceutical firm Sanofi as part of a research and development collaboration agreement in January 2019 and secured $120m from pharmaceutical firm Pfizer in August 2018, also as part of a strategic agreement.
The company did not specify whether either of these two investments formed part of the series B round.
Founded in 2008, Biontech is working on immunotherapies for cancer and infectious diseases. It advances research by co-founder and chief executive Uğur Şahin,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
